ClinicalTrials.gg
RecruitingNCT07258563TASTY-steeringUpdated Jul 15, 2026

The TASTY-steering Study

An interventional study of Taste steering in Metastatic Triple Negative Breast Cancer, Metastatic Testicular Cancer and Stage II-IV Diffuse Large B Cell Lymphoma, sponsored by University Medical Center Groningen. Recruiting at 11 sites in Netherlands. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by University Medical Center Groningen · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jun 2025, registered Nov 2025).
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Triple Negative Breast Neoplasms with a site in Netherlands — 8 open to participants now, 14 under way, 4 of them phase 3. Triple Negative Breast Neoplasms · Netherlands.

Planned enrollment
16th of 31
201 · median 201
Started
2025
with 3 others
No phase
Only one
of the 32
Primary completion
2028-07
later than 8 of 13 live
Registered
32nd of 32
by date

Among the 32 studies in Triple Negative Breast Neoplasms with a site in Netherlands, this one is the 16th largest by planned enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2025, is the only one with no phase, reaches primary completion later than 8 of the 13 other live ones, and was the 32nd registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

8 of the 32 studies in Triple Negative Breast Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Triple Negative Breast Neoplasms with a site in Netherlands, or all of them as a file.
02

Study summary

This is a multicentre non-blinded randomised intervention trial with a parallel cluster design. The multicentre study will be performed at 12 hospitals in the Netherlands. A parallel cluster design per hospital was selected to prevent contact between participants in the same hospital who are randomised into different study arms. Such contact may result in bias as it may allow for patients in the control arm to be informed about elements of taste steering.

To examine the effect of at-home taste steering versus standard care on food enjoyment, the obtained results and outcomes will be measured 1) at baseline before chemotherapy is started, 2) at week 0 when taste or smell alterations occur, and 3) after 6 weeks. The taste steering will take place at home. The control group will receive usual care. Questionnaires will be filled in online at home, while taste and smell tests and saliva collection will be conducted either at home or in the hospital during regular visits. Patients in both study arms are contacted by their dietitian every 3 weeks.

Some hospitals have implemented elements of taste steering. However, these elements are focused on patients who are admitted to the hospital, and therefore only interfere to a limited extent with the present study that is directed at patients managing their taste alterations at home. Experience with the Smaakpupil tool indicates that the algorithm reaches saturation after 3-4 weeks. Therefore, an intervention period of 6 weeks has been selected.

03

Conditions studied

  • Metastatic Triple Negative Breast Cancer
  • Metastatic Testicular Cancer
  • Stage II-IV Diffuse Large B Cell Lymphoma

Keywords

  • Taste Alterations
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 and ≤70 years
  • Indication to start chemotherapy for:

    • triple negative breast cancer
    • Metastatic testicular cancer
    • Stage II-IV diffuse large B cell lymphoma
  • Chemotherapy scheduled to start in the next 6 weeks
  • Consuming solid foods and drinks is possible
  • ≤50% of recommended daily intake in kcal consists of oral nutritional supplements
  • Oral mucositis grade ≤2 (, version 5.0)
  • Ability to comply with all protocol-required actions
  • Written
  • For the intervention phase only: subjective change in taste since start of chemotherapy

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Currently experiencing taste or smell problems
  • Previous or current radiotherapy of head and neck region
  • Enteral feeding through tube or parenteral feeding
  • Participation in another clinical trial aimed at preventing or treating taste and/or smell alterations
  • Chronic (>1 month) high dose (>10 mg prednisone/day or equivalent).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
201 participants (estimated)

Study arms

  • Experimental
    Taste steering

    To examine the effect of at-home taste steering versus standard care on food enjoyment, the obtained results and outcomes will be measured 1) at baseline before chemotherapy is started, 2) at week 0 when taste or smell alterations occur, and 3) after 6 weeks. The taste steering will take place at home.

    Behavioral: Taste steering

  • No intervention
    No intervention

    standard of care

Interventions

  • BehavioralTaste steering

    To examine the effect of at-home taste steering versus standard care on food enjoyment, the obtained results and outcomes will be measured 1) at baseline before chemotherapy is started, 2) at week 0 when taste or smell alterations occur, and 3) after 6 weeks. The taste steering will take place at home. The control group will receive usual care. Questionnaires will be filled in online at home, while taste and smell tests and saliva collection will be conducted either at home or in the hospital during regular visits. Patients in both study arms are contacted by their dietitian every 3 weeks.

06

What researchers measure

Primary outcomes

  1. Food enjoyment in appetite, hunger and sensory perception

    Food enjoyment, measured by the subsection of the Appetite, Hunger and Sensory Perception Questionnaire (AHSP) after 6 weeks of taste steering compared with standard care. The AHSP uses a 5-point Likert scale (1-5), with higher scores indicating greater appetite, hunger, or sensory changes.

    Time frame: 6 weeks

Secondary outcomes

  1. Food enjoyment and liking

    Food enjoyment and food liking: questions on food enjoyment and food liking on 9-point hedonic scale. Higher scores on the Food enjoyment and food liking indicate more food enjoyment and food liking.

    Time frame: 6 weeks

  2. Health-related quality of life

    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Core-30 item (EORTC QLQ-C30 questionnaire) assesses quality of life. It is measured using 1-4 and 1-7 scales. Higher scores indicate better functioning and global quality of life, and worse symptoms on symptom domains.

    Time frame: 6 weeks

  3. Taste and smell alterations

    The Chemotherapy-induced Taste Alteration Scale (ciTAS-NL) assesses taste and smell alterations across intensity, discomfort, and phantogeusia/parageusia domains. It is measured using a 5-point Likert scale. Higher scores indicate more severe alterations.

    Time frame: 6 weeks

  4. Risk of malnutrition

    The Patient-Generated Subjective Global Assessment Short Form (PG-SGA SF) assesses the risk of malnutrition. It is measured using patient-reported items scored numerically. Scores of 0-3 indicate low risk, 4-8 moderate risk, and ≥9 high risk of malnutrition, with higher scores reflecting greater need for nutritional intervention.

    Time frame: 6 weeks

  5. Dry mouth feeling

    Xerostomia Inventory (XI) Assesses the overall subjective experience and frequency of dry mouth symptoms. It is measured using a 5-point Likert scale (1-5). Higher scores indicate more frequent and severe xerostomia. Regional Oral Dryness Inventory (RODI) Assesses the location-specific experience of oral dryness across different regions of the mouth. It is measured using a 5-point Likert scale (1-5). Higher scores indicate more severe regional oral dryness.

    Time frame: 6 weeks

  6. Taste and smell function

    Taste function measured with taste strips and the smell function measured with Sniffin' Sticks.

    Time frame: 6 weeks

  7. Saliva secretion

    Saliva secretion

    Time frame: 6 weeks

  8. Body weight

    Body weight

    Time frame: 6 weeks

07

Study locations

6 of 11 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2028, 37 months after the start.

Of 49 interventional studies with no phase under Triple Negative Breast Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 36. This study's planned 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 2, 2025
StartActual
Jun 6, 2025
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07258563
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Jun 6, 2025
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Jul 15, 2026

Study contacts

J. J. de Haan, MD, PhD
Contact
j.j.de.haan@umcg.nl
+31 50 361 2821
M. D. Douma
Contact
m.d.douma@umcg.nl
+31 50 361 4603
J. J. de Haan, MD, PhD
principal investigator · University Medical Center Groningen, Dept. of Medical Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion